Marek N.
- Country
- Poland
- Department
- 5212: Klinika Alergologii
Research Overview
- Evaluation of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, and Mast Cell Activation Syndrome: A Phase 2 Multicenter Study
- Evaluation of Mepolizumab for Achieving Clinical Remission in Patients with Severe Asthma: A Prospective, Real-World Interventional Study
- Evaluation of the Efficacy and Safety of Fluticasone Propionate/Salbutamol Sulfate in Reducing Severe Asthma Exacerbations in Asthma Patients
Data & Insights
Has run more than one trial at 87 of 317 partner sites.
Specializations
Respiratory Medicine
This investigator specializes in treating various forms of severe asthma, with particular emphasis on eosinophilic asthma. Their research explores innovative therapeutic approaches for patients with uncontrolled asthma conditions.
- Severe Eosinophilic Asthma Management
- Asthma Exacerbation Prevention
- Advanced Inhaler Therapy
The investigator evaluates treatments including combination therapies with corticosteroids and targeted biological agents.
Hematological Disorders
The investigator focuses on rare blood and immune system conditions, particularly systemic mastocytosis and related disorders affecting mast cell function.
- Indolent Systemic Mastocytosis
- Mast Cell Activation Syndrome
- Myelofibrosis
Their work encompasses both smoldering and indolent forms of mastocytosis, focusing on symptomatic treatment approaches.
Therapeutic Innovation
The investigator studies novel therapeutic agents for both respiratory and hematological conditions, including targeted molecular therapies and biological treatments.
- Novel Drug Development
- Combination Therapy Approaches
- Long-term Disease Management
Research activities focus on evaluating treatment efficacy in patients unresponsive to conventional therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.